Nutriband Advances Abuse Deterrent Technology with New Patent
Introduction to Nutriband's Innovative Technology
Nutriband has taken a significant step forward in its mission to enhance the safety of transdermal drug delivery systems. The company has recently filed a provisional patent application aimed at advancing its AVERSA™ transdermal abuse deterrent technology. This innovative approach is especially relevant for patches that deliver opioids and stimulants, substances known for their potential for misuse.
Details of the Provisional Patent Application
By filing this provisional patent application with the U.S. Patent and Trademark Office, Nutriband is working to solidify its intellectual property rights and protect its proprietary technology. The focus of this application is on improving the formulations and coating methods that make the AVERSA™ technology more effective in deterring abuse.
Enhanced Security Features
The new patent covers formulations and application methods designed to elevate the abuse deterrent capabilities of Nutriband’s technology. This is an important development; should this provisional patent transition to a non-provisional filing and receive approval, Nutriband could extend the protection period significantly for its technology and products derived from it.
The Scope of AVERSA™ Abuse Deterrent Technology
AVERSA™ technology employs a unique coating with an aversive agent that induces a negative taste experience, deterring individuals from abusing the medication through unauthorized routes. This is crucial for reducing the risk of accidental ingestion and increasing overall safety for end users.
International Intellectual Property Portfolio
Nutriband has built a robust global portfolio of patents, with protections in 46 countries, including major markets like the United States, Europe, and Japan. This international presence not only reinforces Nutriband's position in the market but also highlights the universal importance of its technology in combating drug abuse.
Market Impact and Future Prospects
With the rising concerns about opioid misuse and the general challenges associated with drug abuse, Nutriband's AVERSA™ technology presents a timely solution. It aims to enhance the safety profile of transdermal delivery systems while ensuring that patients who genuinely need these medications can access them without additional risk.
About Nutriband Inc.
Nutriband Inc. specializes in developing a range of transdermal pharmaceutical products. Its flagship project involves creating an abuse-deterrent fentanyl patch utilizing the AVERSA™ technology. This approach underscores the company's commitment to advancing healthcare solutions that prioritize both efficacy and safety.
Conclusion
The recent provisional patent application by Nutriband underscores its determination to lead in the field of safe drug delivery. As awareness grows regarding the dangers of drug abuse, technologies like AVERSA™ will become increasingly vital. This innovative advance may contribute significantly to transforming how opioids and stimulants are administered, aiming for a safer future for patients and healthcare providers alike.
Contact Information
Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com
Frequently Asked Questions
What is Nutriband's AVERSA™ technology?
AVERSA™ is a transdermal drug delivery system designed to deter abuse through the use of an aversive flavoring agent.
Why is the provisional patent important?
The provisional patent enhances Nutriband's intellectual property protection and helps secure the innovative aspects of its technology.
In how many countries is Nutriband's technology protected?
Nutriband has patents issued in 46 countries worldwide, ensuring broad global protection for its innovations.
How does AVERSA™ prevent drug abuse?
The technology includes a coating that produces a negative taste experience, discouraging unauthorized consumption.
What is the primary focus of Nutriband Inc.?
Nutriband is dedicated to developing a portfolio of effective and safe transdermal pharmaceutical products with a focus on abuse deterrent technologies.
About The Author
Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.